Vol 7, No 4 (2021)
Research paper
Published online: 2022-01-31
Page views 5124
Article views/downloads 28
Get Citation

Connect on Social Media

Connect on Social Media

Epidemiological evaluation of paediatric psoriasis patients at the Dermatology Department

Natalia Bień1, Klaudia Lipińska1, Michał Niedźwiedź2, Małgorzata Skibińska2, Joanna Maria Narbutt2, Aleksandra Lesiak2
Forum Dermatologicum 2021;7(4):100-103.

Abstract

Introduction: Psoriasis is a chronic autoinflammatory disease, which mostly affects skin and joints. Patients with psoriasis are at risk of developing comorbidities such as diabetes, cardiovascular diseases or mental disorders. It is reported that even one-third of the total psoriatic cases may have skin symptoms in childhood. 

Material and methods: The study aimed to perform a retrospective analysis of paediatric patients with psoriasis admitted to the dermatological department between 2018 and 2020. Patients’ data were analysed for age, gender, medical diagnosis (ICD-10) including subtypes of psoriasis, treatment, the clinical course of the disease and results of the diagnostic tests including cholesterol fractions and blood glucose level. 

Results: In the years 2018–2020 73 children were admitted to the dermatological department. The number of female patients 47 (64.38%) significantly dominated over the number of male patients 26 (35.62%). Almost 95% of them were diagnosed with psoriasis vulgaris. Only 3 cases (4.11%) of generalized pustular psoriasis and 1 case (1.37%) of psoriatic arthritis were reported. Almost 20% of children had a positive family history of psoriasis. Readmission to the ward was required in 35.62% of the cases. 23.4% of patients presented abnormality in lipid profile. 15% had various comorbidities. 

Conclusions: Better understanding of psoriasis and its management from an early age, may improve the quality of life of psoriasis patients and prevent them from developing serious comorbidities in the future.

Article available in PDF format

Add to basket: 49.00 PLN

Aready have access?

References

  1. Kim HO, Kang SY, Kim JC, et al. Pediatric Psoriasis: From New Insights into Pathogenesis to Updates on Treatment. Biomedicines. 2021; 9(8).
  2. Relvas M, Torres T. Pediatric Psoriasis. Am J Clin Dermatol. 2017; 18(6): 797–811.
  3. Tangtatco JA, Lara-Corrales I. Update in the management of pediatric psoriasis. Curr Opin Pediatr. 2017; 29(4): 434–442.
  4. Eichenfield LF, Paller AS, Tom WL, et al. Pediatric psoriasis: Evolving perspectives. Pediatr Dermatol. 2018; 35(2): 170–181.
  5. Tkach V, Voloshynovych M, Girnyk G, et al. Clinical features and the course of psoriasis in children. Dermatology Review. 2020; 107(5): 476–480.
  6. Gupta R, Debbaneh MG, Liao W. Genetic Epidemiology of Psoriasis. Curr Dermatol Rep. 2014; 3(1): 61–78.
  7. Bronckers IM, Paller AS, van Geel MJ, et al. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Paediatr Drugs. 2015; 17(5): 373–384.
  8. Wierzbowska-Drabik K, Lesiak A, Skibińska M, et al. Psoriasis and Atherosclerosis-Skin, Joints, and Cardiovascular Story of Two Plaques in Relation to the Treatment with Biologics. Int J Mol Sci. 2021; 22(19).
  9. Cordoro KM. Management of childhood psoriasis. Adv Dermatol. 2008; 24(3): 125–169.
  10. Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020; 82(1): 161–201.
  11. Kang BY, O'Haver J, Andrews ID. Pediatric Psoriasis Comorbidities: Screening Recommendations for the Primary Care Provider. J Pediatr Health Care. 2021; 35(3): 337–350.
  12. Salvastru CM, Cretu S, Tiplica GS. Pediatric psoriasis—Epidemiology and disease particularities. J Am Acad Dermatol. 2016; 74(5): AB215.
  13. Goenaga-Vázquez Y, Lauck KC, Hebert AA. Therapeutic challenges in managing pediatric psoriasis. Int J Womens Dermatol. 2020; 7(3): 314–318.
  14. Haulrig MB, Zachariae C, Skov L. Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic. Psoriasis (Auckl). 2021; 11: 1–20.
  15. Dziennik Urzędowy Ministra Zdrowia. Leczenie umiarkowanej i ciężkiej postaci łuszczycy plackowatej, załącznik B47 (od 11–2021). https://www.gov.pl/attachment/7f4be6f1-e46e-414a-87ad-6b7a321328c2.
  16. Narbutt J, Reich A, Adamski Z, et al. Psoriasis in children. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1. Dermatol Rev. 2021; 108(4): 239–257.
  17. Narbutt J, Reich A, Adamski Z, et al. Psoriasis in children. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2. Dermatol Rev. 2021.
  18. Barter P. HDL-C: role as a risk modifier. Atheroscler Suppl. 2011; 12(3): 267–270.